NRX Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
NRX Pharmaceuticals, Inc. (NRXP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 25.00 thousand shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-14
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 25.00K shares, a 94.97% decline year-over-year.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 110.14K shares, a 120.27% increase year-over-year.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 44.87K shares.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 0.00 shares, a 100.00% decline from fiscal 2023.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 90.00K shares, a 95.12% decline from fiscal 2022.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.84M shares, a 106.75% increase from fiscal 2021.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 892.22K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 25.00K shares 10-Q · filed 2026-08-14 | 135.13K shares derived: sum of 2 quarters · filed 2026-08-14 | 180.00K shares derived: sum of 3 quarters · filed 2026-08-14 | 180.00K shares derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | 110.14K shares 10-Q · filed 2026-08-14 | 155.00K shares derived: sum of 2 quarters · filed 2026-08-14 | 155.00K shares derived: sum of 3 quarters · filed 2026-08-14 | 652.00K shares derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | 44.87K shares derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-14 | 44.87K shares derived: sum of 2 quarters · filed 2026-08-14 | 541.87K shares derived: sum of 3 quarters · filed 2026-08-14 | 591.87K shares 10-Q · filed 2026-08-14 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 497.00K shares derived: sum of 2 quarters · filed 2025-11-14 | 547.00K shares 10-Q · filed 2025-11-14 | 547.00K shares derived: sum of 4 quarters · filed 2026-03-23 | |
| 2025-06-30 | 497.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | 547.00K shares 10-Q · filed 2025-08-18 | 547.00K shares derived: sum of 3 quarters · filed 2026-03-23 | 547.00K shares derived: sum of 4 quarters · filed 2026-03-23 | |
| 2025-03-31 | 50.00K shares 10-Q · filed 2025-05-15 | 50.00K shares derived: sum of 2 quarters · filed 2026-03-23 | 50.00K shares derived: sum of 3 quarters · filed 2026-03-23 | 50.00K shares derived: sum of 4 quarters · filed 2026-03-23 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-23 | 0.00 shares derived: sum of 3 quarters · filed 2026-03-23 | 0.00 shares 10-K · filed 2026-03-23 | |
| 2024-09-30 | 0.00 shares 10-Q · filed 2024-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2024-11-14 | 0.00 shares 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | 0.00 shares 10-Q · filed 2024-08-14 | 0.00 shares 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-14 | ||||
| 2023-12-31 | 90.00K shares 10-K · filed 2025-03-14 | 900.00K shares 10-K · filed 2024-03-29 | |||
| 2023-03-31 | 0.00 shares 10-Q · filed 2024-05-14 | 862.64K shares derived: sum of 2 quarters · filed 2024-05-14 | 942.64K shares derived: sum of 3 quarters · filed 2024-05-14 | 1.29M shares derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | 862.64K shares derived: 10-K 12 month − 3 quarters · filed 2023-03-31 | 942.64K shares derived: sum of 2 quarters · filed 2023-03-31 | 1.29M shares derived: sum of 3 quarters · filed 2023-03-31 | 1.84M shares 10-K · filed 2023-03-31 | |
| 2022-09-30 | 80.00K shares 10-Q · filed 2022-11-14 | 430.00K shares derived: sum of 2 quarters · filed 2022-11-14 | 982.00K shares derived: sum of 3 quarters · filed 2022-11-14 | ||
| 2022-06-30 | 350.00K shares 10-Q · filed 2022-11-14 | 902.00K shares derived: sum of 2 quarters · filed 2022-11-14 | |||
| 2022-03-31 | 552.00K shares 10-Q · filed 2022-11-14 | ||||
| 2021-12-31 | 892.22K shares 10-K · filed 2023-03-31 | ||||
| 2021-03-31 | 210.80K shares 10-Q/A · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |